Healthcare Professionals

TIF Presents The Federation’s Annual Report For 2020
Actualités

TIF Presents The Federation’s Annual Report For 2020

“Our commitment to unite the patient voice and to advocate at the highest possible levels for equal access to all treatment options remains our number one priority.“ TIF President –…
TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education
Actualités de TIF

TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education

Read. Learn. Empower. The Thalassaemia International Federation´s internationally acclaimed Educational Programme is a fundamental component of TIF´s work and is specifically designed for and addressed to the ever-growing learning needs…
Hemoglobin Disorders In Europe: A Systematic Effort Of Identifying And Addressing Unmet Needs And Challenges By TIF
Actualités

Hemoglobin Disorders In Europe: A Systematic Effort Of Identifying And Addressing Unmet Needs And Challenges By TIF

The recent population movement has led to a steady increase of carriers and patients with haemoglobin disorders, namely thalassaemia and sickle cell disease, in all countries of the European Union.…
It’s Here: The 4th Edition Of TIF Guidelines For The Management of TDT
Actualités

It’s Here: The 4th Edition Of TIF Guidelines For The Management of TDT

TIF, its Board of Directors, and its International Scientific Advisory Board proudly present the 4th Edition of the Federation’s most prestigious and renowned publication, the TIF Guidelines For The Management…
MONTHLY UPDATE: COVID-19 Developing Vaccinations & Therapeutic Drugs
Publications

MONTHLY UPDATE: COVID-19 Developing Vaccinations & Therapeutic Drugs

All the latest updates of TIF’s Vaccinations & Therapeutic Drugs Guide for COVID-19 gathered in one single document.
TIF Presents Its Newly Launched SCD Educational Course for Healthcare Professionals On 9 April
Actualités

TIF Presents Its Newly Launched SCD Educational Course for Healthcare Professionals On 9 April

TIF is delighted to announce the organisation of a Virtual Presentation Event of the ‘TIF Sickle Cell Disease Educational Course for Healthcare Professionals’ – an online course providing comprehensive information…
Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy
Actualités

Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy

The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing therapy GPH101 by Graphite Bio to initiate a Phase 1/2…
EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia
Actualités

EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia

The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an investigational CRISPR-Cas9 gene editing therapy for patients with transfusion dependent β-thalassaemia. This marks the first…
TIF European Thalassaemia & Sickle Cell Disease Symposium To Take Place On 11-13 December 2020
Actualités

TIF European Thalassaemia & Sickle Cell Disease Symposium To Take Place On 11-13 December 2020

TIF is proudly organising the European Thalassaemia & Sickle Cell Disease Symposium, a joint patients’ and healthcare professionals’ three-day educational event which will take place online on 11 – 13 December…
Virtual Conference on Alpha Thalassaemia Major By UCSF on 8-9 January 2021
Actualités

Virtual Conference on Alpha Thalassaemia Major By UCSF on 8-9 January 2021

The Center for Maternal-Fetal Precision Medicine (UCSF) will host a 2-day online international conference on Alpha Thalassaemia Major, which was once considered universally fatal in utero, on 8-9 January 2021. …
Bouton retour en haut de la page